Navigation Links
Novel anticancer strategy moves from laboratory to clinic
Date:1/3/2008

Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important "intercept points" for cancer cells.

The results of research on the compound in mice appear in the Jan. 1 issue of Cancer Research. The article is highlighted on the cover.

The compound was used for the first time in human patients with solid tumors in 2007.

The idea behind the intercept point strategy is to shut down the transmission of a large number of growth signals in cancer cells at once, says senior author Donald L. Durden, MD, PhD, professor of pediatrics at Emory University School of Medicine and the Emory Winship Cancer Institute.

Dr. Durden, scientific director of the Aflac Cancer Center and Blood Disorders Service at Children's Healthcare of Atlanta, compares a cancer cell to a building with too many of the lights left on.

"Doctors have been trying to treat cancer by turning out the lights in one room at a time, instead of going after the transformer box," he says.

Dr. Durden and his colleagues targeted a class of enzymes called PI-3 kinases, which represent an intercept point and occupy valuable real estate in almost every cell in the body.

"Nature made these enzymes central in controlling growth, differentiation and survival," he says. But you can't hit only one of them; they're redundant."

The intercept point concept of drug development was featured in a December 2007 review in Nature Clinical Practice Neurology by the Durden laboratory.

Scientists have found genes that encode the PI-3 kinases to be mutated in a large number of tumor types, putting them in overdrive. In addition, a single enzyme that opposes PI-3 kinases, called the PTEN phosphatase, is inactivated in a large fraction of human prostate, brain, endometrial and breast cancers--between 20 and 50 percent depending on the cell type.

In the Cancer Research article, Dr. Durden and his colleagues show that a chemical inhibitor of all PI-3 kinases, modified with a tag that directs the compound to the blood vessels needed by growing tumors, stops the growth of seven types of tumors in mice.

The compound, called SF1126, is active against prostate, breast, renal, multiple myeloma, neuroblastoma, glioblastoma and rhabdomyosarcoma, the authors show.

The first author of the Cancer Research article is Joseph Garlich, PhD, chief scientific officer of Semafore Pharmaceuticals. The firm and Dr. Durden collaborated on identifying the SF1126 compound, based on his work while on the faculty at Indiana University School of Medicine.

At the end of 2007, doctors in Arizona and Indiana began to test SF1126 in a phase I clinical trial in people with solid tumors. Another phase I trial for multiple myeloma patients will begin at Emory's Winship Cancer Institute and elsewhere in 2008. It is anticipated that SF1126 will enter pediatric cancer trials within one year.

Scientists use PI-3 kinase inhibitors in test-tube experiments every day; however, the enzyme-inhibiting part of SF1126 was never used clinically despite its identification more than a decade ago.

"It was a total non-drug: toxic, insoluble and broke down too fast," Dr. Durden says.

Attaching the tag, called a RGD peptide, makes the inhibitor dissolve easier and last longer in the body. It also lets molecules on blood vessel walls grab the compound and send it into tumors, the authors show.

Tumors send out chemical signals for new blood vessels when they don't have enough oxygen. The authors found that in mice, the compound prevents tumors from growing new blood vessels by inhibiting part of their response to the lack of oxygen. SF1126 also sensitizes human tumors in mice to a chemotherapy agent called taxotere.

The authors found that tumor cell lines artificially engineered to be more "addicted" to PI-3 kinase growth signals are more sensitive to the drug. That predicts that some patients' tumors could be more sensitive than others, Dr. Durden says.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology: